CymaBay Therapeutics Inc (CBAY.OQ)
13.74USD
22 Jun 2018
$-0.11 (-0.79%)
$13.85
$13.83
$13.99
$13.35
5,590,930
325,901
$15.59
$5.04
About
Overall
| Beta: | 2.08 |
| Market Cap(Mil.): | $358.81 |
| Shares Outstanding(Mil.): | 43.76 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| CBAY.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 82.81 | 32.74 |
| EPS (TTM): | -1.06 | -- | -- |
| ROI: | -182.71 | 2.00 | 14.38 |
| ROE: | -308.78 | 3.49 | 16.08 |
BRIEF-CymaBay Therapeutics Q1 Loss Per Share $0.32
* CYMABAY REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-CymaBay Initiates Phase 2B Study Of Seladelpar In Patients With Non-Alcoholic Steatohepatitis
* CYMABAY THERAPEUTICS ANNOUNCES THE INITIATION OF A PHASE 2B STUDY OF SELADELPAR IN PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS
BRIEF-Cymabay Announces 12-Week And 26-Week Results From Phase 2 Study Of Seladelpar In Patients With Primary Biliary Cholangitis
* WEEK RESULTS FROM ITS ONGOING PHASE 2 STUDY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS AT THE INTERNATIONAL LIVER CONGRESS™ 2018
BRIEF-Cymabay Reports Q4 Loss Per Share $0.11
* CYMABAY REPORTS FOURTH QUARTER AND FISCAL 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-CymaBay Announces Proposed Public Offering Of Common Stock
* CYMABAY THERAPEUTICS INC - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND ONGOING DEVELOPMENT OF SELADELPAR Source text for Eikon: Further company coverage:
BRIEF-Cymabay Therapeutics Receives $5 Mln Milestone Payment For Arhalofenate From Kowa Pharmaceuticals America
* CYMABAY THERAPEUTICS RECEIVES $5 MILLION MILESTONE PAYMENT FOR ARHALOFENATE FROM KOWA PHARMACEUTICALS AMERICA Source text for Eikon: Further company coverage:
BRIEF-Cymabay Therapeutics Says First Primary Biliary Cholangitis Patients Have Been Successfully Enrolled In Seladelpar Long-Term Extension Study
* CYMABAY THERAPEUTICS INC - FIRST PRIMARY BILIARY CHOLANGITIS PATIENTS HAVE BEEN SUCCESSFULLY ENROLLED IN SELADELPAR LONG-TERM EXTENSION STUDY Source text for Eikon: Further company coverage:
BRIEF-CymaBay Therapeutics Files For Mixed Shelf Of Up To $200 Mln
* CYMABAY THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2pRWkXa) Further company coverage:
Estimates